Specialists in Rare Disease Therapies
Aegerion Pharmaceuticals UK is a biopharmaceutical company dedicated to improving the lives of people affected by serious and rare diseases. As a wholly owned subsidiary of Amryt Pharma, we are part of a global organization that develops and delivers innovative therapies for conditions with high unmet medical needs.
Incorporated in 2012 and headquartered in London, Aegerion UK focuses on the distribution, access, and regulatory oversight of treatments for lipid and metabolic disorders in the UK and surrounding markets.
Our History
Founded as part of Aegerion Pharmaceuticals Inc., the UK branch became a strategic player in the European rare disease market through the launch of Juxtapid® (lomitapide) for Homozygous Familial Hypercholesterolemia (HoFH). In 2019, Aegerion Pharmaceuticals was acquired by Amryt Pharma, significantly expanding the company’s global footprint and portfolio of approved therapies.
Our sweet clients say
James R., 34, HoFH patient from Manchester
CUSTOMER
“Before starting Juxtapid®, I had exhausted every treatment option available. Since beginning therapy, my cholesterol levels have finally stabilized — and with them, my quality of life has improved more than I thought possible.”
Lucy B., Clinical Pharmacist, London
CUSTOMER
“Aegerion’s commitment to rare disease care goes beyond the prescription. Their support programs and responsiveness have made it easier for our clinic to provide timely, appropriate care to complex patients.”
Angela D., Mother of a 10-year-old patient
CUSTOMER
“Watching my daughter suffer from complications of lipodystrophy was heartbreaking. Myalept® has made an extraordinary difference. She’s now able to attend school more regularly and live more like other kids her age.”
David M., Health Technology Consultant
CUSTOMER
“Aegerion Pharmaceuticals UK consistently delivers on quality, compliance, and timing — crucial when dealing with patients who rely on uninterrupted access to specialized medications.”